JP2021153461A - Anti-stress composition - Google Patents
Anti-stress composition Download PDFInfo
- Publication number
- JP2021153461A JP2021153461A JP2020056467A JP2020056467A JP2021153461A JP 2021153461 A JP2021153461 A JP 2021153461A JP 2020056467 A JP2020056467 A JP 2020056467A JP 2020056467 A JP2020056467 A JP 2020056467A JP 2021153461 A JP2021153461 A JP 2021153461A
- Authority
- JP
- Japan
- Prior art keywords
- stress
- lactic acid
- lactococcus
- lactis
- acid bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002180 anti-stress Effects 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 120
- 241000894006 Bacteria Species 0.000 claims abstract description 60
- 239000004310 lactic acid Substances 0.000 claims abstract description 60
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 60
- 241000194036 Lactococcus Species 0.000 claims abstract description 45
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 40
- 229940076279 serotonin Drugs 0.000 claims description 19
- 241000194035 Lactococcus lactis Species 0.000 claims description 18
- 235000014897 Streptococcus lactis Nutrition 0.000 claims description 18
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 14
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 14
- 230000028327 secretion Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 229960000890 hydrocortisone Drugs 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 5
- 230000009471 action Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 20
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 17
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 17
- 230000035882 stress Effects 0.000 description 16
- 230000009182 swimming Effects 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000003340 mental effect Effects 0.000 description 9
- 241000282412 Homo Species 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000012048 forced swim test Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000037328 acute stress Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000037326 chronic stress Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000003863 physical function Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010054089 Depressive symptom Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000007149 gut brain axis pathway Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008326 skin blood flow Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本発明は、ラクトコッカス属の乳酸菌を含有する抗ストレス組成物に関する。 The present invention relates to an anti-stress composition containing a lactic acid bacterium of the genus Lactococcus.
乳酸菌は、代謝によって乳酸を産生する細菌類の総称であり、その形状によって乳酸桿菌と乳酸球菌に分類される。ラクトコッカス属は、生乳やチーズなどの発酵によく用いられている通性嫌気性の乳酸球菌に属する（非特許文献１参照）。ラクトコッカス属の乳酸菌摂取による健康へ与える効果として、例えば免疫賦活作用（例えば、特許文献１および２参照）、疲労回復もしくは疲労蓄積予防作用（特許文献３参照）などが報告されている。一方、現代社会において問題視されているストレスやうつ症状に対するラクトコッカス属の有効性については不明な点が多い。 Lactobacillus is a general term for bacteria that produce lactic acid by metabolism, and is classified into lactic acid bacilli and lactic acid cocci according to their shape. The genus Lactococcus belongs to a facultative anaerobic lactic acid bacterium that is often used for fermentation of raw milk and cheese (see Non-Patent Document 1). As effects on health by ingestion of lactic acid bacteria of the genus Lactococcus, for example, immunostimulatory action (see, for example, Patent Documents 1 and 2), fatigue recovery or fatigue accumulation prevention action (see Patent Document 3) and the like have been reported. On the other hand, there are many unclear points about the effectiveness of Lactococcus for stress and depressive symptoms, which are regarded as problems in modern society.
脳と腸との相互作用は脳腸相関とも呼ばれ、液性因子（ホルモンやサイトカインなど）や自律神経系の経路を介して、相互に情報伝達を行っていると考えられている。これまでの研究により、生体における腸内細菌叢の有無でストレス応答が変化することから、腸内細菌とストレスには何らかの関連性があると考えられている（非特許文献２参照）。また、乳発酵物を有効成分として含有するストレス由来の皮膚血流低下改善用組成物が開示されている（特許文献４参照）。しかしながら、ラクトコッカス属の乳酸菌自体が抗ストレス作用を有することは全く知られていない。 The interaction between the brain and the intestine is also called the gut-brain axis, and it is thought that information is transmitted to each other via humoral factors (hormones, cytokines, etc.) and the pathways of the autonomic nervous system. According to previous studies, the stress response changes depending on the presence or absence of the intestinal bacterial flora in the living body, and thus it is considered that there is some relationship between the intestinal bacteria and stress (see Non-Patent Document 2). Further, a composition for improving a decrease in skin blood flow derived from stress containing a fermented milk product as an active ingredient is disclosed (see Patent Document 4). However, it is not known at all that Lactococcus lactic acid bacteria themselves have an anti-stress effect.
本発明者らは、ラクトコッカス属の乳酸菌を含有する組成物を対象に投与することにより抗ストレス効果を奏することが分かった。本発明はこれらの知見に基づくものである。 The present inventors have found that administration of a composition containing a lactic acid bacterium of the genus Lactococcus to a subject exerts an anti-stress effect. The present invention is based on these findings.
従って、本発明は、ラクトコッカス属の乳酸菌を含有する抗ストレス組成物を提供する。 Therefore, the present invention provides an anti-stress composition containing a lactic acid bacterium of the genus Lactococcus.
本発明によれば以下の発明が提供される。
（１）ラクトコッカス属の乳酸菌を含有する、抗ストレス組成物。
（２）ラクトコッカス属の乳酸菌が死菌体である、（１）に記載の抗ストレス組成物。
（３）ラクトコッカス属の乳酸菌が加熱死菌体である、（１）に記載の抗ストレス組成物。
（４）ラクトコッカス属の乳酸菌が、ラクトコッカス・ラクティス・サブスピーシーズ・ラクティスＮＦＲＣＬ−１１（Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． ｌａｃｔｉｓ ＮＦＲＣＬ−１１）である、（１）〜（３）のいずれかに記載の抗ストレス組成物。
（５）ストレス低減のために用いられる、（１）〜（４）のいずれかに記載の抗ストレス組成物。
（６）セロトニンの分泌を促進するために用いられる、（１）〜（５）のいずれかに記載の抗ストレス組成物。
（７）コルチゾールまたはコルチコステロン分泌の上昇を抑制するために用いられる、（１）〜（５）のいずれかに記載の抗ストレス組成物。
（８）抗ストレス食品組成物である、（１）〜（７）のいずれかに記載の抗ストレス組成物。
（９）ラクトコッカス属の乳酸菌を含有する、抗ストレス剤。
（１０）ラクトコッカス属の乳酸菌を、対象に摂取させることを含んでなる、ストレス低減方法（但し、ヒトに対する医療行為を除く）。
According to the present invention, the following inventions are provided.
(1) An anti-stress composition containing a lactic acid bacterium of the genus Lactococcus.
(2) The anti-stress composition according to (1), wherein the lactic acid bacterium of the genus Lactococcus is a dead cell.
(3) The anti-stress composition according to (1), wherein the lactic acid bacterium of the genus Lactococcus is a heat-killed cell.
(4) The anti-stress according to any one of (1) to (3), wherein the lactic acid bacterium of the genus Lactococcus is Lactococcus lactis subspecis lactis NFRCL-11. Composition.
(5) The anti-stress composition according to any one of (1) to (4), which is used for stress reduction.
(6) The anti-stress composition according to any one of (1) to (5), which is used to promote the secretion of serotonin.
(7) The anti-stress composition according to any one of (1) to (5), which is used to suppress an increase in cortisol or corticosterone secretion.
(8) The anti-stress composition according to any one of (1) to (7), which is an anti-stress food composition.
(9) An anti-stress agent containing a lactic acid bacterium belonging to the genus Lactococcus.
(10) A stress-reducing method (excluding medical practice for humans), which comprises ingesting a lactic acid bacterium of the genus Lactococcus to a subject.
本発明の組成物を用いることにより、抗ストレス効果を奏する点で有利である。 The use of the composition of the present invention is advantageous in that it exerts an anti-stress effect.
［微生物の寄託］
ラクトコッカス・ラクティス・サブスピーシーズ・ラクティスＮＦＲＣＬ−１１株（Lactococcus lactis subsp.lactis NFRCL-11）は、２０２０年２月２６日付け（寄託日）で独立行政法人製品評価技術基盤機構 特許微生物寄託センターに、受託番号ＮＩＴＥ Ｐ−０３１４１として寄託されている。
[Deposit of microorganisms]
Lactococcus lactis subsp.lactis NFRCL-11 strain (Lactococcus lactis subsp.lactis NFRCL-11) became the Patent Microorganisms Depositary Center of the National Institute of Technology and Evaluation on February 26, 2020 (deposit date). , Deposited as accession number NITE P-03141.
本発明の抗ストレス組成物は、ラクトコッカス属の乳酸菌を含有するものであり、有効成分として含んでいてもよい。本発明の組成物に含有するラクトコッカス属の乳酸菌は、生菌体でも死菌体でもいずれでもよいが、死菌体であることが好ましく、加熱死菌体であることがより好ましく、加熱死菌体粉末であることがさらに好ましい。加熱死菌体は、例えば、生菌体を９５℃以上で１０分間程度加熱して得ることができる。 The anti-stress composition of the present invention contains a lactic acid bacterium of the genus Lactococcus and may be contained as an active ingredient. The lactic acid bacterium of the genus Lactococcus contained in the composition of the present invention may be either a live cell or a dead cell, but is preferably a dead cell, more preferably a heat-killed cell, and heat-killed. It is more preferably a cell powder. The heat-killed cells can be obtained, for example, by heating the viable cells at 95 ° C. or higher for about 10 minutes.
本発明の組成物に含有するラクトコッカス属の乳酸菌は、特に限定されるものではないが、Lactococcus lactis subsp.lactis（ラクトコッカス・ラクティス・サブスピーシーズ・ラクティス）、Lactococcus lactis subsp. cremoris、およびLactococcus lactis subsp. hordniaeなどが挙げられ、これらの中でもLactococcus lactis subsp.lactis（ラクトコッカス・ラクティス・サブスピーシーズ・ラクティス）が好ましい。 The lactic acid bacteria of the genus Lactococcus contained in the composition of the present invention are not particularly limited, but are Lactococcus lactis subsp.lactis (Lactococcus lactis subsp. Cremoris), Lactococcus lactis subsp. Cremoris, and Lactococcus lactis. Subsp. Hordniae and the like are mentioned, and among these, Lactococcus lactis subsp.lactis (Lactococcus lactis subspice lactis) is preferable.
本発明の組成物にLactococcus lactis subsp.lactis（ラクトコッカス・ラクティス・サブスピーシーズ・ラクティス）が含まれる場合、Lactococcus lactis subsp.lactis（ラクトコッカス・ラクティス・サブスピーシーズ・ラクティス）であれば特に限定されるものではないが、Lactococcus lactis subsp.lactis NBRC12007、Lactococcus lactis subsp.lactis NFRC3、Lactococcus lactis subsp.lactis NFRC4、Lactococcus lactis subsp.lactis NFRC7、Lactococcus lactis subsp.lactis NFRC9、Lactococcus lactis subsp.lactis NFRC10、またはLactococcus lactis subsp.lactis NFRC11が好ましく、Lactococcus lactis subsp.lactis NBRC12007、Lactococcus lactis subsp.lactis NFRC10、またはLactococcus lactis subsp.lactis NFRC11がより好ましく、Lactococcus lactis subsp.lactis NFRC11が特に好ましい。 When the composition of the present invention contains Lactococcus lactis subsp.lactis (Lactococcus lactis subsp.lactis), it is particularly limited as long as it is Lactococcus lactis subsp.lactis (Lactococcus lactis subsp.lactis). Lactococcus lactis subsp.lactis NBRC12007, Lactococcus lactis subsp.lactis NFRC3, Lactococcus lactis subsp.lactis NFRC4, Lactococcus lactis subsp.lactis NFRC7, Lactococcus lactis subsp.lactis NFRC9 subsp.lactis NFRC11 is preferred, Lactococcus lactis subsp.lactis NBRC12007, Lactococcus lactis subsp.lactis NFRC10, or Lactococcus lactis subsp.lactis NFRC11 is more preferred, and Lactococcus lactis subsp.lactis NFRC11 is particularly preferred.
本発明において、「ストレス」とは、種々の外部刺激が負担として働くとき、心身に生じる機能変化を意味し、「抗ストレス」とはこの機能変化を起こさせないことを意味する。「抗ストレス」とは、種々の外部刺激が負担として働いて心身に機能変化が生じた後にその機能変化を元の状態に戻すもしくは近づけること、種々の外部刺激が負担として働いても心身の機能変化が生じないもしくは生じにくくすること、またはそもそも種々の外部刺激が心身の負担として働かないもしくは働きにくくすることなどを意味する。本明細書において、「ストレス低減」とは、種々の外部刺激が負担として働いても心身の機能変化が生じないもしくは生じにくくすることを意味する。本発明の好ましい態様によれば、ラクトコッカス属の乳酸菌を含有する、ストレス低減のために用いられる抗ストレス組成物である。本発明のより好ましい態様によれば、急性ストレス低減のために用いられる抗ストレス組成物である。ここで、急性ストレスとは、短期的な外部刺激によって心身に生じる機能変化であり、例えば外部刺激が継続的もしくは断続的に１日以内負荷されること、好ましくは１時間以内に負荷されること、より好ましくは１０分以内に負荷されることに起因するものを意味する。急性ストレスの例としては、筆記テスト、朝の満員電車、長時間残業のストレスなどの比較的短期間のストレスが挙げられる。一方、ここで、慢性ストレスとは、長期的な外部刺激によって心身に生じる機能変化であり、例えば、外部刺激が継続的もしくは断続的に１日より長期にわたり負荷されることに起因するものを意味する。慢性ストレスの例としては、学校や勤務先での比較的長期間の人間関係のあつれきなどといった長期間持続するストレスが挙げられる。また、本発明のより好ましい別の態様によれば、精神的および／または身体的な外部刺激によるストレス低減のために用いられる抗ストレス組成物である。ここで、ストレスを生じさせる要因には、精神的（人間関係のあつれき、過密環境など）、身体的（長時間残業、過度の運動など）、物理的（紫外線、騒音、温熱環境など）、化学的（ホルムアルデヒドなどの化学物質）、生物学的（ウイルス、細菌、寄生虫）な外部刺激などが挙げられるが、本発明の好ましい態様によれば、本発明の組成物は、これらの中でも特に精神的および／または身体的な外部刺激によるストレスをより低減することができる。なお、下記本願の実施例における強制水泳試験は精神的および身体的な混合刺激であると考えられる。 In the present invention, "stress" means a functional change that occurs in the mind and body when various external stimuli act as a burden, and "anti-stress" means that this functional change is not caused. "Anti-stress" means that after various external stimuli work as a burden and a functional change occurs in the mind and body, the functional change is returned to or close to the original state, and even if various external stimuli work as a burden, the mental and physical functions It means that changes do not occur or are difficult to occur, or that various external stimuli do not work or are difficult to work as a physical and mental burden. As used herein, the term "stress reduction" means that even if various external stimuli act as burdens, mental and physical functional changes do not occur or are less likely to occur. According to a preferred embodiment of the present invention, it is an anti-stress composition used for stress reduction, which contains a lactic acid bacterium of the genus Lactococcus. According to a more preferred embodiment of the present invention, it is an anti-stress composition used for reducing acute stress. Here, the acute stress is a functional change caused in the mind and body by a short-term external stimulus, for example, the external stimulus is continuously or intermittently loaded within one day, preferably within one hour. , More preferably due to being loaded within 10 minutes. Examples of acute stress include relatively short-term stress such as written tests, crowded trains in the morning, and stress of long overtime. On the other hand, here, chronic stress is a functional change caused in the mind and body by a long-term external stimulus, and means, for example, a result of the external stimulus being continuously or intermittently applied for a longer period than one day. do. Examples of chronic stress include long-lasting stress, such as relatively long-term relationships at school or work. Also, according to another more preferred embodiment of the present invention, it is an anti-stress composition used for reducing stress due to mental and / or physical external stimuli. Here, the factors that cause stress include mental (human relations, overcrowded environment, etc.), physical (long overtime, excessive exercise, etc.), physical (ultraviolet rays, noise, thermal environment, etc.), Chemical (chemical substances such as formaldehyde), biological (viruses, bacteria, parasites) external stimuli and the like can be mentioned, and according to a preferred embodiment of the present invention, the composition of the present invention is particularly among these. The stress caused by external mental and / or physical stimuli can be further reduced. The forced swimming test in the examples of the present application below is considered to be a mixed mental and physical stimulus.
本発明のより好ましい態様によれば、ラクトコッカス属の乳酸菌を含有する、セロトニンの分泌を促進するために用いられる抗ストレス組成物である。ここで、セロトニンは、生理活性アミンの一種で、生体内でトリプトファンから合成され、脳、胃腸、血液中などに多く含まれ、脳の神経伝達などに作用するとともに、精神を安定させる作用もある。すなわち、セロトニンは、種々の外部刺激が負担として働いても心身の機能変化が生じないもしくは生じにくくすることができる。 According to a more preferred embodiment of the present invention, it is an anti-stress composition containing a lactic acid bacterium of the genus Lactococcus and used for promoting the secretion of serotonin. Here, serotonin is a kind of bioactive amine, which is synthesized from tryptophan in the living body, is contained in a large amount in the brain, gastrointestinal tract, blood, etc., and acts on nerve transmission in the brain and also has an effect of stabilizing the mind. .. That is, serotonin can prevent or prevent changes in mental and physical functions even when various external stimuli act as burdens.
本発明のさらに好ましい態様によれば、ラクトコッカス属の乳酸菌を含有する、コルチゾールまたはコルチコステロン分泌の上昇を抑制するために用いられる抗ストレス組成物である。ここで、コルチゾールおよびコルチコステロンは、副腎皮質ホルモンである糖質コルチコイドの一種で、精神の安定に密接に関連するホルモンであり、コルチゾールはヒトなどの霊長類においてみられるホルモンであり、コルチコステロンはラットやマウスなどの齧歯類においてみられるホルモンである。 According to a more preferred embodiment of the present invention, it is an anti-stress composition containing a lactic acid bacterium of the genus Lactococcus and used for suppressing an increase in cortisol or corticosterone secretion. Here, cortisol and corticosterone are a type of glucocorticoid, which is a corticosteroid, and are hormones closely related to mental stability. Cortisol is a hormone found in primates such as humans, and corticosterone. Is a hormone found in rodents such as rats and mice.
本発明の組成物中のラクトコッカス属の乳酸菌の含有量は、特に限定されるものではないが、例えば、本発明の組成物中に１×１０９個以上含まれ、好ましくは１×１０９〜１×１０１２個含まれ、より好ましくは１×１０９〜１×１０１１個含まれ、さらに好ましくは１×１０９〜１×１０１０個含まれ、特に好ましくは１×１０９〜５×１０９個含まれる。これらの含有量は、加熱処理した死菌体粉末を含有させたときの含有量であってもよい。 The content of Lactococcus lactic acid bacteria in the composition of the present invention is not particularly limited, but for example, 1 × 10 9 or more are contained in the composition of the present invention, preferably 1 × 10 9. ~ 1 × 10 12 pieces, more preferably 1 × 10 9 ~ 1 × 10 11 pieces, further preferably 1 × 10 9 ~ 1 × 10 10 pieces, particularly preferably 1 × 10 9 ~ 5 × 10 9 pieces are included. These contents may be the contents when the heat-treated killed cell powder is contained.
本発明の組成物は、ラクトコッカス属の乳酸菌単独、または他の成分と混合して使用することもできる。他の成分としては、例えば、γ-アミノ酪酸（ＧＡＢＡ）やテアニンのようなアミノ酸や、ユビキノール（還元型コエンザイムＱ１０）のような抗酸化物質などが挙げられる。 The composition of the present invention can be used alone or in combination with other components of Lactococcus lactic acid bacteria. Examples of other components include amino acids such as γ-aminobutyric acid (GABA) and theanine, and antioxidants such as ubiquinol (reduced coenzyme Q10).
本発明の別の好ましい態様によれば、ラクトコッカス属の乳酸菌を含有する、抗ストレス食品組成物が提供される。ラクトコッカス属の乳酸菌を含有する組成物を食品に含有させて、食品組成物として提供することもできる。本発明の組成物を含有させる食品としては、特に限定されるものではないが、例えば、サプリメント、飲料、発酵食品、ご飯類、パン、麺類、または菓子などが挙げられる。 According to another preferred embodiment of the present invention, an anti-stress food composition containing a lactic acid bacterium of the genus Lactococcus is provided. A composition containing a lactic acid bacterium of the genus Lactococcus may be contained in a food and provided as a food composition. The food containing the composition of the present invention is not particularly limited, and examples thereof include supplements, beverages, fermented foods, rice, bread, noodles, and confectionery.
本発明の別の好ましい態様によれば、ラクトコッカス属の乳酸菌を含有する、抗ストレス剤が提供される。本発明の抗ストレス剤には、ラクトコッカス属の乳酸菌を有効成分として含有していてもよい。 According to another preferred embodiment of the present invention, an anti-stress agent containing a lactic acid bacterium of the genus Lactococcus is provided. The anti-stress agent of the present invention may contain a lactic acid bacterium of the genus Lactococcus as an active ingredient.
本発明の別の好ましい態様によれば、ラクトコッカス属の乳酸菌を含有する、抗ストレス医薬組成物（医薬品）が提供される。医薬品（医薬組成物）とは、製剤化のために許容されうる添加剤を併用して、常法に従って、経口製剤または非経口製剤として調製したものである。医薬品が経口製剤の場合には、錠剤、散剤、細粒剤、顆粒剤、カプセル剤、丸剤、徐放剤などの固形製剤、溶液、懸濁液、乳濁液などの液状製剤の形態をとることができる。なお、患者への摂取（投与）の簡易性の点からは、医薬品では、経口製剤であることが好ましい。ここで、製剤化のために許容されうる添加剤には、例えば、賦形剤、安定剤、防腐剤、湿潤剤、乳化剤、滑沢剤、甘味料、着色料、香料、緩衝剤、酸化防止剤、ｐＨ調整剤などが挙げられる。 According to another preferred embodiment of the present invention, an anti-stress pharmaceutical composition (pharmaceutical product) containing a lactic acid bacterium of the genus Lactococcus is provided. A pharmaceutical product (pharmaceutical composition) is prepared as an oral preparation or a parenteral preparation according to a conventional method by using an additive that is acceptable for formulation in combination. When the drug is an oral preparation, the form of a solid preparation such as tablets, powders, fine granules, granules, capsules, pills and sustained-release agents, and liquid preparations such as solutions, suspensions and emulsions is used. Can be taken. From the viewpoint of simplicity of ingestion (administration) to patients, oral preparations are preferable as pharmaceuticals. Here, additives that are acceptable for formulation include, for example, excipients, stabilizers, preservatives, wetting agents, emulsifiers, lubricants, sweeteners, colorants, flavors, buffers, antioxidants. Examples include agents and pH adjusters.
本発明の別の態様によれば、ラクトコッカス属の乳酸菌を、対象（好ましくは、抗ストレスが必要な対象）に摂取させることを含んでなる、ストレス低減方法が提供される。ラクトコッカス属の乳酸菌の対象への摂取は単回でも複数回でもよいが、単回であっても本発明の効果を奏することができる点で有利である。本発明の好ましい態様によれば、ラクトコッカス属の乳酸菌を、対象（好ましくは、抗ストレスが必要な対象）に摂取させることを含んでなる、ストレス低減方法（ヒトに対する医療行為を除く）が提供される。本明細書において、「ヒトに対する医療行為」とは、医師等の処方を必要として、ヒトに対して医薬品を摂取させる（投与する）行為などを意味する。対象には、ヒト以外の動物（馬、牛などの家畜、犬、猫などの愛玩動物、動物園などで飼育されている鑑賞動物など）も包含される。 According to another aspect of the present invention, there is provided a stress reducing method comprising feeding a subject (preferably a subject in need of anti-stress) a lactic acid bacterium of the genus Lactococcus. Lactococcus lactic acid bacteria may be ingested once or multiple times, but it is advantageous in that the effects of the present invention can be achieved even if the ingestion is single times. According to a preferred embodiment of the present invention, there is provided a stress reduction method (excluding medical practice for humans) comprising feeding a subject (preferably a subject in need of anti-stress) a lactic acid bacterium of the genus Lactococcus. Will be done. As used herein, the term "medical practice for humans" means an act of ingesting (administering) a drug to a human, requiring a prescription from a doctor or the like. The target also includes animals other than humans (livestock such as horses and cows, pet animals such as dogs and cats, and ornamental animals bred in zoos and the like).
本発明の別の好ましい態様によれば、ラクトコッカス属の乳酸菌を、対象（好ましくは、抗ストレスが必要な対象）に摂取させることを含んでなる、セロトニン分泌促進方法が提供される。本発明の別のより好ましい態様によれば、ラクトコッカス属の乳酸菌を、対象（好ましくは、抗ストレスが必要な対象）に摂取させることを含んでなる、セロトニン分泌促進方法（ヒトに対する医療行為を除く）が提供される。 According to another preferred embodiment of the present invention, there is provided a method for promoting serotonin secretion, which comprises ingesting a lactic acid bacterium of the genus Lactococcus to a subject (preferably a subject in need of anti-stress). According to another more preferred embodiment of the present invention, a method for promoting serotonin secretion (medical practice for humans) comprising feeding a subject (preferably a subject in need of anti-stress) a lactic acid bacterium of the genus Lactococcus. Except) is provided.
本発明の別の好ましい態様によれば、ラクトコッカス属の乳酸菌を、対象（好ましくは、抗ストレスが必要な対象）に摂取させることを含んでなる、コルチゾールまたはコルチコステロン分泌上昇抑制方法が提供される。本発明の別のより好ましい態様によれば、ラクトコッカス属の乳酸菌を、対象（好ましくは、抗ストレスが必要な対象）に摂取させることを含んでなる、コルチゾールまたはコルチコステロン分泌上昇抑制方法（ヒトに対する医療行為を除く）が提供される。 According to another preferred embodiment of the present invention, there is provided a method for suppressing an increase in cortisol or corticosterone secretion, which comprises ingesting a lactic acid bacterium of the genus Lactococcus to a subject (preferably a subject in need of anti-stress). Will be done. According to another more preferred embodiment of the present invention, a method for suppressing an increase in cortisol or corticosterone secretion, which comprises ingesting a lactic acid bacterium of the genus Lactococcus to a subject (preferably a subject in need of anti-stress). (Excluding medical practice for humans) is provided.
本発明の別の態様によれば、抗ストレスのための食品組成物または医薬組成物の製造に用いられるラクトコッカス属の乳酸菌の使用が提供される。 According to another aspect of the present invention, the use of Lactococcus lactic acid bacteria used in the production of food compositions or pharmaceutical compositions for anti-stress is provided.
本発明の別の態様によれば、抗ストレスのためのラクトコッカス属の乳酸菌の使用が提供される。 According to another aspect of the invention, the use of Lactococcus lactic acid bacteria for anti-stress is provided.
本発明の別の態様によれば、抗ストレスのためのラクトコッカス属の乳酸菌が提供される。 According to another aspect of the invention, a lactic acid bacterium of the genus Lactococcus for anti-stress is provided.
本発明の抗ストレス剤や、抗ストレス医薬組成物におけるラクトコッカス属の乳酸菌等は、本発明の組成物と同じであってもよい。 The anti-stress agent of the present invention, lactic acid bacteria of the genus Lactococcus in the anti-stress pharmaceutical composition, and the like may be the same as the composition of the present invention.
以下、実施例により本発明をより具体的に説明するが、本発明の技術的範囲はこれらに限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples, but the technical scope of the present invention is not limited thereto.
試験例１：乳酸菌のセロトニン（５−ＨＴ）分泌作用の評価
培養細胞として、ＲＩＮ−１４Ｂ細胞（腸管分泌細胞様の培養細胞）（ＡＴＣＣ（American Type Culture Collection）から入手）を用いた。また、乳酸菌として、新潟県農業総合研究所食品研究センター保有菌株（ＮＦＲＣ株）を６株と、独立行政法人製品評価技術基盤機構保有菌株（ＮＢＲＣ株）を５株との合計１１菌株を事前に９５℃以上で１０分間加熱処理した死菌体粉末を以下の試験で用いた。試験に使用した乳酸菌の１１菌株は下記表１および図１に記載の通りである。
Test Example 1: use as a lactic acid bacteria of serotonin (5-HT) Evaluation cultured cells Secretion, RIN-14B cells (cell culture intestinal secretory cell-like) (obtained from ATCC (A merican T ype C ulture C ollection)) board. In addition, as lactic acid bacteria, a total of 11 strains, including 6 strains owned by the Food Research Center of the Niigata Prefectural Agricultural Research Institute (NFRC strain) and 5 strains owned by the Independent Administrative Institution Product Evaluation Technology Infrastructure Organization (NBRC strain), were prepared in advance. Killed cell powders heat-treated at 95 ° C. or higher for 10 minutes were used in the following tests. The 11 strains of lactic acid bacteria used in the test are as shown in Table 1 and FIG. 1 below.
細胞培養プレートの各ウエルにＲＩＮ−１４Ｂ細胞を２×１０５ｃｅｌｌ／ｗｅｌｌとなるように播種し、播種後に乳酸菌の死菌体粉末を１００μｇ／ｍＬとなるように添加した。当該乳酸菌の死菌体粉末を添加しないものをコントロール（Control）とした。死菌体粉末の添加後に、インキュベータで３７℃、５％ＣＯ２で１時間培養した。培養後にＥＬＩＳＡキット（Ｅｎｚｏ社製）を用いて、ＥＬＩＳＡ法により細胞上清中に分泌されたセロトニン濃度を測定し、Controlと比較した。その結果を、下記表１および図１に示す。 RIN-14B cells were seeded in each well of the cell culture plate so as to be 2 × 10 5 cell / well, and after seeding, killed cell powder of lactic acid bacteria was added so as to be 100 μg / mL. The one to which the killed cell powder of the lactic acid bacterium was not added was defined as Control. After the addition of the killed cell powder, the cells were cultured in an incubator at 37 ° C. and 5% CO 2 for 1 hour. After culturing, the concentration of serotonin secreted into the cell supernatant was measured by the ELISA method using an ELISA kit (manufactured by Enzo), and compared with Control. The results are shown in Table 1 and FIG. 1 below.
表１および図１の結果から、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＢＲＣ１２００７、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ３、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ４、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ７、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ９、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ１０、およびＬａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ１１はセロトニン量比が１．２より高くセロトニンの分泌量が多いことから抗ストレス効果が高く、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＢＲＣ１２００７、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ１０、およびＬａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ１１はセロトニン量比が２．０より高くセロトニンの分泌量が多いことから抗ストレス効果がより高く、Ｌａｃｔｏｃｏｃｃｕｓ ｌａｃｔｉｓ ｓｕｂｓｐ． Ｌａｃｔｉｓ ＮＦＲＣ１１はセロトニン量比が３．０より高くセロトニンの分泌量が多いことから抗ストレス効果が特に高いことが分かった。 From the results of Table 1 and FIG. 1, Lactococcus lactis subsp. Lactis NBRC12007, Lactococcus lactis subsp. Lactis NFRC3, Lactococcus lactis subsp. Lactis NFRC4, Lactococcus lactis subsp. Lactis NFRC7, Lactococcus lactis subsp. Lactis NFRC9, Lactococcus lactis subsp. Lactis NFRC10, and Lactococcus lactis subsp. Lactis NFRC11 has a high anti-stress effect because the serotonin amount ratio is higher than 1.2 and the amount of serotonin secreted is large, and Lactococcus lactis subsp. Lactis NBRC12007, Lactococcus lactis subsp. Lactis NFRC10, and Lactococcus lactis subsp. Lactis NFRC11 has a higher anti-stress effect because the serotonin content ratio is higher than 2.0 and the amount of serotonin secreted is higher, and Lactococcus lactis subsp. It was found that Lactis NFRC11 has a particularly high anti-stress effect because the serotonin amount ratio is higher than 3.0 and the amount of serotonin secreted is large.
試験例２：強制水泳試験
８週齢のＢＡＬＢ／ｃマウス（日本クレア社より入手）を４群に分け、各群ｎ＝６〜７として、以下の表２の試験工程で試験を行った。
試験群は以下の通りである。
第１群：水を経口投与（強制水泳試験（Forced swim test: ＦＳＴ）未実施）（−ＦＳＴ）
第２群：水を経口投与（強制水泳試験実施）（＋ＦＳＴ）
第３群：フルオキセチンを経口投与（２０ｍｇ／ｋｇ−ＢＷ）（ポジティブコントロール；抗うつ剤として市販）（強制水泳試験実施）（＋ＦＳＴ）
第４群：乳酸菌（ラクトコッカス・ラクティス・サブスピーシーズ・ラクティスＮＦＲＣＬ−１１）を経口投与（強制水泳試験実施）（＋ＦＳＴ）
※第４群の乳酸菌は加熱殺菌してマウス１匹当りの投与量が１×１０９個となるように調製して経口投与した。
The test groups are as follows.
Group 1: Oral administration of water (Forced swim test (FST) not performed) (-FST)
Group 2: Oral administration of water (compulsory swimming test conducted) (+ FST)
Group 3: Oral administration of fluoxetine (20 mg / kg-BW) (Positive control; marketed as antidepressant) (Forced swimming test conducted) (+ FST)
Group 4: Oral administration of lactic acid bacteria (Lactococcus lactis subspecies lactis NFRCL-11) (forced swimming test conducted) (+ FST)
※ lactic acid bacteria of the fourth group of the dose of murine per animal and heat sterilization were prepared to orally administered so that 1 × 10 9 cells.
強制水泳試験は、マウスを水槽（シリンダーサイズ：φ２０×５００ｍｍ、水温：２３〜２５℃、水嵩：１５ｃｍ）に入れて行った。強制水泳試験後直ぐに採血を行い、血漿中のコルチコステロン濃度（ｎｇ／ｍｌ）を、ＥＬＩＳＡキット（Ｅｎｚｏ社製）を用いて測定した。その結果を図２に示す。 The forced swimming test was carried out by placing the mouse in a water tank (cylinder size: φ20 × 500 mm, water temperature: 23 to 25 ° C., water volume: 15 cm). Blood was collected immediately after the forced swimming test, and the plasma corticosterone concentration (ng / ml) was measured using an ELISA kit (manufactured by Enzo). The result is shown in FIG.
強制水泳試験の結果によれば、第２群（水を経口投与（強制水泳試験実施））および第３群（フルオキセチンを経口投与（強制水泳試験実施））は、第１群（水を経口投与（強制水泳試験未実施））に比べて血漿中のコルチコステロン濃度は有意に増加した。一方、第４群（乳酸菌を経口投与（強制水泳試験実施））は、第２群および第３群に比べて血漿中のコルチコステロン濃度が低く、第１群に比べて有意な増加は見られなかった。 According to the results of the forced swimming test, the second group (oral administration of water (compulsory swimming test)) and the third group (oral administration of fluoxetin (compulsory swimming test)) were the first group (oral administration of water). (Forced swimming test not conducted)), the concentration of corticosterone in plasma increased significantly. On the other hand, in the 4th group (oral administration of lactic acid bacteria (forced swimming test)), the plasma corticosterone concentration was lower than that in the 2nd and 3rd groups, and a significant increase was observed as compared with the 1st group. I couldn't.
従って、ラクトコッカス属の乳酸菌（特に、ラクトコッカス・ラクティス・サブスピーシーズ・ラクティスＮＦＲＣＬ−１１）を有効成分として含有する組成物を用いることにより、血漿中のコルチコステロン濃度が低下して、水泳によるストレスが軽減されていることが分かり、当該組成物を抗ストレス組成物として用いることができることが分かった。 Therefore, by using a composition containing a lactic acid bacterium belonging to the genus Lactococcus (particularly, Lactococcus lactis subspices lactis NFRCL-11) as an active ingredient, the concentration of corticosterone in plasma is reduced, and swimming is performed. It was found that the stress was reduced, and it was found that the composition could be used as an anti-stress composition.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020056467A JP2021153461A (en) | 2020-03-26 | 2020-03-26 | Anti-stress composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020056467A JP2021153461A (en) | 2020-03-26 | 2020-03-26 | Anti-stress composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021153461A true JP2021153461A (en) | 2021-10-07 |
Family
ID=77915933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020056467A Pending JP2021153461A (en) | 2020-03-26 | 2020-03-26 | Anti-stress composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2021153461A (en) |
-
2020
- 2020-03-26 JP JP2020056467A patent/JP2021153461A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI583388B (en) | Use of lactobacillus plantarum for manufacturing anti-fatigue probiotic composition for improve exercise performance | |
| CN105025909B (en) | Stress-reducing agent | |
| KR20080059581A (en) | Composition for improving intestinal flora | |
| WO2007038466A2 (en) | Treatment of bipolar disorder utilizing anti-fungal compositions | |
| JP6596135B2 (en) | Composition for improving intestinal environment, inhibiting weight gain by ingesting a high-fat diet, or inhibiting H. pylori | |
| JP2009542204A (en) | Functional lactic acid bacteria fermentation composition excellent in diet effect | |
| JP2014196339A (en) | Composition for prevention or treatment of anemia | |
| US20200078414A1 (en) | Method of preventing or treating obesity using a novel strain of parabacteroides goldsteinii | |
| TW201918251A (en) | Akkermansia muciniphila proliferation material | |
| JP2019513786A (en) | Bifidobacterium for increasing lean body mass | |
| JP2011116666A (en) | Anti-stress agent containing lactic bacterium-fermented royal jelly and method for producing the same | |
| JP6793380B2 (en) | Evaluation method, screening method and manufacturing method of substances that suppress the rise in blood glucose level due to sucrose intake | |
| CN114262677B (en) | Lactobacillus plantarum and application thereof in preventing and/or treating inflammatory bowel disease | |
| US9833484B2 (en) | Conjugated linoleic acid-producing strains of probiotic bacteria and use thereof for the preparation of a food, dietetic or pharmaceutical composition | |
| JP4540376B2 (en) | Lactic acid bacteria production substances | |
| US20210379121A1 (en) | Probiotics and probiotic compositions having modified carbohydrate metabolism | |
| US20240156884A1 (en) | Agent for improving mitochondrial function | |
| CN110279119A (en) | Mixing probiotics Nagqu 4580 (Nagqu 4580) is applied in the food for alleviating depression | |
| JP2021153461A (en) | Anti-stress composition | |
| JP2009044971A (en) | New yeast which adds probiotic effect on ruminant farm animal to lactobacillus for silage preparation and use thereof | |
| CN111743921B (en) | Application of lactobacillus paracasei or metabolite thereof in preparation of composition for promoting fatty acid metabolism | |
| KR102629519B1 (en) | Bacillus amyloliquefaciens strain for improving blood levels of TMAO and TMA elevated by high protein and high choline intake | |
| RU2437663C2 (en) | Method of correcting intestinal microflora | |
| JP6675521B1 (en) | Lactic acid bacteria, blood iron increaser, and anemia improver | |
| WO2021132453A1 (en) | Capillary blood vessel disorder inhibiting agent, capillary blood vessel disorder ameliorating agent, and capillary angiogenesis accelerating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230201 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240514 |